Ceftriaxone is a third-generation cephalosporin that was approved for use in the US in 1984 and is still widely used today. Ceftriaxone is available in different brands, which is available in a parenteral formulation. It is indicated for the treatment of moderate-to-severe bacterial infections caused by susceptible organisms and can be given intravenously or intramuscularly. A 58 year old male patient has been admitted in the hospital on 28-DEC-2021, with existing complaints of Altered behavior, decreased appetite, melena and ecchymosis. Based on the lab investigations and physical examination, patient had a definitive diagnosis reported as “Decompensated chronic liver disease With portal hypertension and Hepatic encephalopathy”. Upon administration of Ciftriaxone at a dose of 1gram- intravenously, the patient has developed erythematic rash over the chest. The severity of ADR was assessed using Modified Hartwig and Siegel Severity Scale, by which the severity of this ADR stands at level 3 Moderate ADR, as the ADR was well managed by suspect product withheld, discontinued or use of antidote or alternative treatment. We conclude that to avoid drug-induced difficulties in a patient, we should always monitor the prescription with drug relevant problems (DRP's). Particularly in patients who have other chronic problems such as liver disease or high blood pressure. This prescription monitoring will ensure that we provide the safest and most effective treatment at the lowest possible cost.
Impact Factor
2022: 6.012
This work is licensed under a